Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Messina

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Pain and Symptom Management|June 29, 2010
Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough painSteven D Passik, John Messina, Anthony Golsorkhi, et al.
Anesthesia and Analgesia|February 10, 2011
The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic painMichael A Ashburn, Kieran A Slevin, John Messina, et al.
Pain Medicine (Malden, Mass.)|September 3, 2010
A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic painJohn T Farrar, John Messina, Fang Xie, et al.
The Journal of Supportive Oncology|August 22, 2007
Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic painNeal E Slatkin, Fang Xie, John Messina, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|March 12, 2004
Rivastigmine for Alzheimer's Disease: Improvement Versus Reduced WorseningMurray Raskind, Vinod Kumar, Lisa Malaty, et al.
Headache|September 3, 2013
Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powderMohammad Obaidi, Elliot Offman, John Messina, et al.
Journal of Clinical Pharmacology|June 8, 2011
Assessment of the relative potency of fentanyl buccal tablet to intravenous morphine in healthy volunteers using a thermally induced hyperalgesia pain modelDavid L Saunders, John Messina, Mona Darwish, et al.
Clinical Neuropharmacology|May 1, 2002
Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmineStanford S Jhee, Thomas Shiovitz, Richard D Hartman, et al.
Pediatrics in Review|June 3, 2011
Index of Suspicion. Case 1: Status epilepticus, hypertension, and tachycardia in a 5-year-old boy. Case 2: Cardiopulmonary arrest during gymnastics practice in a teenage girl. Case 3: Acute renal failure in a teenage boy who has autism and picaCorey Chartan, Elizabeth Aarons, Aliva De, et al.
Headache|October 31, 2014
A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study)Roger K Cady, Peter J McAllister, Egilius L H Spierings, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Pain and Symptom Management|June 29, 2010
Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough painSteven D Passik, John Messina, Anthony Golsorkhi, et al.
Anesthesia and Analgesia|February 10, 2011
The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic painMichael A Ashburn, Kieran A Slevin, John Messina, et al.
Pain Medicine (Malden, Mass.)|September 3, 2010
A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic painJohn T Farrar, John Messina, Fang Xie, et al.
The Journal of Supportive Oncology|August 22, 2007
Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic painNeal E Slatkin, Fang Xie, John Messina, et al.
Primary Care Companion to the Journal of Clinical Psychiatry|March 12, 2004
Rivastigmine for Alzheimer's Disease: Improvement Versus Reduced WorseningMurray Raskind, Vinod Kumar, Lisa Malaty, et al.
Headache|September 3, 2013
Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powderMohammad Obaidi, Elliot Offman, John Messina, et al.
Journal of Clinical Pharmacology|June 8, 2011
Assessment of the relative potency of fentanyl buccal tablet to intravenous morphine in healthy volunteers using a thermally induced hyperalgesia pain modelDavid L Saunders, John Messina, Mona Darwish, et al.
Clinical Neuropharmacology|May 1, 2002
Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmineStanford S Jhee, Thomas Shiovitz, Richard D Hartman, et al.
Pediatrics in Review|June 3, 2011
Index of Suspicion. Case 1: Status epilepticus, hypertension, and tachycardia in a 5-year-old boy. Case 2: Cardiopulmonary arrest during gymnastics practice in a teenage girl. Case 3: Acute renal failure in a teenage boy who has autism and picaCorey Chartan, Elizabeth Aarons, Aliva De, et al.
Headache|October 31, 2014
A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study)Roger K Cady, Peter J McAllister, Egilius L H Spierings, et al.
Pageof 3